Search Result

Results for "

alpha(4)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Amyloid-β (2) Apoptosis (1) Bacterial (2) Cholinesterase (ChE) (3) ERK (1) Fluorescent Dye (1) GABA Receptor (6) Integrin (31) Isotope-Labeled Compounds (6) Kinesin (2) Microtubule/Tubulin (1) nAChR (63) NF-κB (2) Opioid Receptor (1) p38 MAPK (1) PI5P4K (1) Potassium Channel (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (29) Metabolic Disease (1) Neurological Disease (70)

112

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: α-synuclein 5 alpha Reductase PGC-1α

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15770

TR-14035 4 Publications Verification	Integrin	Inflammation/Immunology
TR-14035 is a orally active dual α₄β₇/α₄β₁ integrin antagonist, with IC₅₀ s of 7 nM and 87 nM for α₄β₇ and α₄β₁, respectively. TR-14035 can be used for the research of inflammation and autoimmune diseases .

HY-15536A

Cebranopadol ((1α,4α)stereoisomer) GRT6005 (1α,4α)stereoisomer	Opioid Receptor	Neurological Disease
Cebranopadol ((1α,4α)stereoisomer) is a stereoisomer of cebranopadol. Cebranopadol is a potent agonist activity on ORL-1.

HY-P9911A

Vedolizumab (anti-α4β7-integrin)	Integrin	Inflammation/Immunology
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .

HY-P9911

Vedolizumab 1 Publications Verification Anti-Human lymphocyte α4β7 integrin, Humanized Antibody	Integrin	Inflammation/Immunology Cancer
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.

HY-N10525

3α,4β-Galactotriose

Others Others

3α,4β-Galactotriose is a galactosyl residue .

3α,4β-Galactotriose	Others	Others
3α,4β-Galactotriose is a galactosyl residue .

HY-D1486

4,4-Difluoro-8-(4'-iodophenyl)-1,7-bis-(1'-napthyl)-4-bora-3alpha,4alpha-diaza-s-indacene	Fluorescent Dye	Others
4,4-Difluoro-8-(4'-iodophenyl)-1,7-bis-(1'-napthyl)-4-bora-3alpha,4alpha-diaza-s-indacene is a fluorescent dye for DNA sequencing .

HY-138542

RO0270608	Integrin	Inflammation/Immunology
RO0270608, the active metabolite of R411, is a dual **alpha4beta1-alpha4beta7 (α4β1/α4β7)** integrin antagonist. Antiinflammatory activity .

HY-103066

Br-PBTC	nAChR	Neurological Disease
Br-PBTC is a potent, 2/4 subtype-selective positive allosteric modulator of nAChRs (nicotinic acetylcholine receptors) with α2β2，α2β4，α4β2，α4β4，(α4β2)₂α4 and (α4β2)₂β2 EC₅₀ ranges from 0.1~0.6 μM. Br-PBTC acts from the c-tail of an α subunit .

HY-124290

Carotegrast methyl AJM300	Integrin	Inflammation/Immunology
Carotegrast methyl (AJM300) is an orally active and selective α4 integrin antagonist. HCA2969, an active metabolite of Carotegrast methyl, is a specific and dual α4β1/α4β7 integrin antagonist. Carotegrast methyl prevents the development of colitis in mice .

HY-75385

Zaurategrast ethyl ester CDP323; UCB1184197	Integrin	Inflammation/Immunology
Zaurategrast ethyl ester (CDP323), the ethyl ester proagent of CT7758 , is a *α4β1/α4β7* integrin antagonist used for the treatment of inflammatory and autoimmune disorders .

HY-75385A

Zaurategrast ethyl ester sulfate CDP323 sulfate; UCB1184197 sulfate	Integrin	Inflammation/Immunology
Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester proagent of CT7758 , is a *α4β1/α4β7* integrin antagonist used for the treatment of inflammatory and autoimmune disorders .

HY-14951

Firategrast 5+ Cited Publications SB 683699	Integrin	Neurological Disease
Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .

HY-70073

Zaurategrast

2 Publications Verification

CT7758
Integrin Inflammation/Immunology

Zaurategrast (CT7758) is a potent and oral-effective α₄-integrin inhibitor .

Zaurategrast 2 Publications Verification CT7758	Integrin	Inflammation/Immunology
Zaurategrast (CT7758) is a potent and oral-effective *α₄-integrin* inhibitor .

HY-136258

nAChR agonist CMPI hydrochloride	nAChR	Neurological Disease
nAChR agonist CMPI hydrochloride is a potent and selective positive allosteric modulator (PAM) of nAChR containing a α4:α4 subunit interface. nAChR agonist CMPI hydrochloride enhances the response of (α4)₃(β2)₂ nAChR to ACh (10 µM) with an EC₅₀ of 0.26 µM. nAChR agonist CMPI hydrochloride has potential for the research of nicotine dependence and many neuropsychiatric conditions associated with decreased brain cholinergic activity .

HY-14126

BIO-1211 2 Publications Verification	Integrin	Inflammation/Immunology
BIO-1211 is a highly selective and orally active α4β1 (VLA-4) inhibitor, with IC₅₀ values of 4 nM and 2 μM for α4β1 and α4β7, respectively .

HY-134130

Integrin modulator 1	Integrin	Inflammation/Immunology
Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC₅₀ of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 increases cell adhesion mediated by α4β1 integrin, with an EC₅₀ of 12.9 nM .

HY-115764

nAChR agonist 2

nAChR Neurological Disease

nAChR agonist 2 (compound 8) is a selective alpha4beta2 (α4β2) nAChR agonist (K_d=26 nM) .
HY-123802

BIO7662

Integrin Cancer

BIO7662 is a specific α4β1 antagonist. BIO7662 can be used to study α4β1 integrin-ligand interactions .

nAChR agonist 2	nAChR	Neurological Disease
nAChR agonist 2 (compound 8) is a selective alpha4beta2 (α4β2) nAChR agonist (K_d=26 nM) .

BIO7662	Integrin	Cancer
BIO7662 is a specific *α4β1* antagonist. BIO7662 can be used to study α4β1 integrin-ligand interactions .

HY-P3522

REDV	Integrin	Cancer
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion .

HY-P3522A

REDV TFA	Integrin	Cancer
REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .

HY-P2267

LDV 1 Publications Verification	Integrin	Others
LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells .

HY-108069

Iptakalim hydrochloride	Potassium Channel nAChR	Neurological Disease
Iptakalim hydrochloride, a lipophilic para-amino compound, is a novel ATP-sensitive potassium channel (K_ATP) opener, as well as an α₄β₂-containing nicotinic acetylcholine receptor (nAChR) antagonist .

HY-110160

Pozanicline dihydrochloride ABT-089 dihydrochloride	nAChR	Neurological Disease
Pozanicline dihydrochloride (ABT-089 dihydrochloride) is an orally bioavailable nicotinic acetylcholine receptor (nAChR) agonist with a K_i of 16.7 nM for binding to [ ³H]cytisine sites . Pozanicline is an *α4β2*-selective nAChR agonist, which binds to rat brain α4β2 nAChR with a K_i of 17 nM while binding to α7 nAChR is insignificant .

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against *α4β7*. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-14189

Valategrast hydrochloride R-411	Integrin	Inflammation/Immunology
Valategrast hydrochloride (R-411) is a potent integrin α4β1 (VLA-4) and *α4β7* dual antagonist. Valategrast hydrochloride has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .

HY-14190

Valategrast R-411 free base	Integrin	Inflammation/Immunology
Valategrast (R-411 free base) is a potent and orally active integrin α4β1 (VLA-4) and *α4β7* dual antagonist. Valategrast has the potential for Chronic obstructive pulmonary disease (COPD) and asthma treatment .

HY-14857

Carotegrast

HCA2969
Integrin Inflammation/Immunology

Carotegrast is an orally available α4 integrin receptor inhibitor with anti-inflammatories activities.

Carotegrast HCA2969	Integrin	Inflammation/Immunology
Carotegrast is an orally available α4 integrin receptor inhibitor with anti-inflammatories activities.

HY-N1064

Xanthoplanine
Xanthoplanine, isolated from theroot of Xylopia parviflora, fully inhibits the EC₅₀ ACh responses of both alpha7 and alpha4beta2 nACh receptors with estimated IC₅₀ values of 9 μM (alpha7) and 5 μM (alpha4beta2) .

HY-136207

TC-2559 difumarate	nAChR	Neurological Disease
TC-2559 idifumarate is a CNS-selective, orally active *α4β2* subtype of nicotinic acetylcholine receptor (nAChR) partial agonist (EC₅₀=0.18 μM). TC-2559 difumarate shows selectivity for α4β2 over α2β4, α4β4 and α3β4 receptors, with EC₅₀s in the range of 10-30 µM. Antinociceptive effect .

HY-107673

RJR-2429 dihydrochloride

nAChR Neurological Disease

RJR 2429 hydrochloride is a α4β2 and α7 nAChR agonist .

RJR-2429 dihydrochloride	nAChR	Neurological Disease
RJR 2429 hydrochloride is a α4β2 and α7 nAChR agonist .

HY-107684

3-Bromocytisine 3-Br-cytisine	nAChR	Neurological Disease
3-Bromocytisine (3-Br-cytisine) is a potent nACh receptors agonist, with IC₅₀s are 0.28, 0.30 and 31.6 nM for hα4β4, hα4β2, and hα7-nACh, respectively. 3-Bromocytisine (3-Br-cytisine) shows different effects on high (HS) and low (LS) ACh sensitivity α4β2 nAChRs with EC₅₀s are 8 and 50 nM, respectively .

HY-129453

BOP sodium	Integrin	Inflammation/Immunology
BOP sodium is a potent and selective dual α9β1/α4β1 integrin inhibitor with K_d values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors. BOP sodium has little inhibitory activity on α4β7, α1β1, α2β1, and α5β1, αIIBβ3 integrins .

HY-107670

Dihydro-β-erythroidine hydrobromide 1 Publications Verification DHβE hydrobromide	nAChR	Neurological Disease
Dihydro-β-erythroidine (DHβE) hydrobromide is a potent, orally active, and competitive antagonist of neuronal nAChRs. Dihydro-β-erythroidine hydrobromide shows selectivity for α4β4 and α4β2 nAChRs, with IC₅₀s of 0.19 and 0.37 μM, respectively. Antidepressant-like activities .

HY-B0379A

Adiphenine hydrochloride	nAChR	Neurological Disease
Adiphenine hydrochloride is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC₅₀s of 1.9, 1.8, 3.7, and 6.3 µM for α1, *α3β4, α4β2, and α4β4*, respectively. Adiphenine hydrochloride has anticonvulsant effects .

HY-110121

NS3861 fumarate	nAChR	Neurological Disease
NS3861 fumarate is an agonist of nicotinic acetylcholine receptors (nAChRs) and binds with high affinity to heteromeric α3β4 nAChR. The binding K_i values of 0.62, 25, 7.8, 55 nM for α3β4, α3β2, α4β4, α4β2, respectively .

HY-110121A

NS3861	nAChR	Neurological Disease
NS3861 is an agonist of nicotinic acetylcholine receptors (nAChRs) and binds with high affinity to heteromeric α3β4 nAChR. The binding K_i values of 0.62, 25, 7.8, 55 nM for α3β4, α3β2, α4β4, α4β2, respectively .

HY-107675

Desformylflustrabromine hydrochloride Deformylflustrabromine hydrochloride; dFBr hydrochloride	nAChR	Neurological Disease
Desformylflustrabromine hydrochloride is a selective agonist of *α₄β₂* neuronal nicotinic acetylcholine receptor (nAChR) with a pEC₅₀ of 6.48.

HY-P1188

LDV-FITC	Integrin	Cancer
LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (K_d: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn ²⁺ respectively). LDV-FITC can be used to detect α4β1 integrin affinity .

HY-B0942

Benzethonium chloride	nAChR Bacterial	Neurological Disease
Benzethonium chloride inhibits nicotinic acetylcholine receptors in human recombinant α7 and α4β2 neurons in Xenopus laevis oocytes.

HY-107589A

BIO5192 hydrate 1 Publications Verification	Integrin	Inflammation/Immunology
BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (K_d<10 pM). BIO5192 hydrate selectively binds to α4β1 (IC₅₀=1.8 nM) over a range of other integrins. BIO5192 hydrate results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .

HY-107589

BIO5192 1 Publications Verification	Integrin	Inflammation/Immunology
BIO5192 is a selective and potent integrin *α4β1* (VLA-4) inhibitor (K_d<10 pM). BIO5192 selectively binds to α4β1 (IC₅₀=1.8 nM) over a range of other integrins. BIO5192 results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .

HY-103520

DS2	GABA Receptor	Neurological Disease
DS2 is a selective positive allosteric modulator of δ-GABA_A receptor. DS2 selectively potentiates GABA responses mediated by α4β3δ receptor. DS2 does not enhance activity at α4β3γ2 and α1β3γ2 receptors. DS2 relieves pain and has the potential for sleep disorders research .

HY-14564A

GTS-21 dihydrochloride 5+ Cited Publications DMXB-A; DMBX-anabaseine	nAChR 5-HT Receptor	Inflammation/Immunology
GTS-21 dihydrochloride is a selective alpha7 nicotinic acetylcholine receptor *(α7-nAChR)* agonist with anti‑inflammatory and cognition‑enhancing activities. GTS-21 dihydrochloride is also a *α4β2* (K_i=20 nM for humanα4β2) and 5-HT3A receptor (IC₅₀=3.1 μM) antagonist .

HY-108831

Natalizumab 1 Publications Verification	Integrin	Inflammation/Immunology
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-10063

Ispronicline TC-1734; ACD3480	nAChR	Neurological Disease
Ispronicline (TC-1734), an orally active, brain-selective *α4β2* nicotine acetylcholine receptor (nAChR) partial agonist, has shown memory-enhancing properties in rodents and a good tolerability profile. Ispronicline binds to the α4β2 nAChR with high affinity (K_i=11 nM) and is highly selective to other nAChRs such as α7 nAChR and α3β4 nAChR .

HY-122247

PVZB1194	Kinesin	Cancer
PVZB1194 is a biphenyl-type inhibitor of Kinesin spindle protein Eg5 or KIF11. Eg5 is related to the cell cycle, and Eg5 inhibition can lead to cell cycle arrest and apoptosis. PVZB1194 exhibits anticancer potential via inhibiting Eg5 ATPase activity. PVZB1194 binds to the α4/α6 allosteric pocket, and shows ATP competetive activity .

HY-14316A

Tebanicline dihydrochloride Ebanicline dihydrochloride; ABT-594 dihydrochloride	nAChR	Neurological Disease
Tebanicline dihydrochloride (Ebanicline dihydrochloride) is a nAChR modulator with potent, orally effective analgesic activity. It inhibits the binding of cytisine to α4β2 neuronal nAChRs with a K_i of 37 pM .

HY-79779S

1-Bromo-4-(bromomethyl)benzene-d6 α,4-Dibromotoluene-d₆	Isotope-Labeled Compounds	Others
1-Bromo-4-(bromomethyl)benzene-d₆ is the deuterium labeled 1-Bromo-4-(bromomethyl)benzene[1].

HY-79779S1

1-Bromo-4-(bromomethyl)benzene-d4 α,4-Dibromotoluene-d₄	Isotope-Labeled Compounds	Others
1-Bromo-4-(bromomethyl)benzene-d₄ is the deuterium labeled 1-Bromo-4-(bromomethyl)benzene[1].

HY-14316B

Tebanicline hydrochloride Ebanicline hydrochloride; ABT-594 hydrochloride	nAChR	Neurological Disease
Tebanicline hydrochloride (Ebanicline hydrochloride) is a nAChR modulator with potent, orally effective analgesic activity. Tebanicline hydrochloride inhibits the binding of cytisine to α4β2 neuronal nAChRs with a K_i of 37 pM .

Cat. No.	Product Name	Target	Research Area

HY-14126

BIO-1211 2 Publications Verification	Integrin	Inflammation/Immunology
BIO-1211 is a highly selective and orally active α4β1 (VLA-4) inhibitor, with IC₅₀ values of 4 nM and 2 μM for α4β1 and α4β7, respectively .

HY-P3522A

REDV TFA	Integrin	Cancer
REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .

HY-P2267

LDV 1 Publications Verification	Integrin	Others
LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells .

HY-P3522

REDV	Integrin	Cancer
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion .

HY-P1188

LDV-FITC	Integrin	Cancer
LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (K_d: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn ²⁺ respectively). LDV-FITC can be used to detect α4β1 integrin affinity .

HY-P3533

EILEVPST	Integrin	Cardiovascular Disease
EILEVPST is a recombinant human fibronectinderived low-molecular-weight peptide fragment. EILEVPST can promote cell type-specific α4 integrin-mediated adhesion. EILEVPST can be used for the research of thrombogenesis .

HY-P5147

α-Conotoxin GID	nAChR	Neurological Disease
α-Conotoxin GID is a paralytic peptide neurotoxin and a selective antagonist of nAChR, with IC₅₀s of 5 nM (α7), 3 nM (α3β2)， 150 nM (α4β2), respectively. α-Conotoxin GID is small disulfide-rich peptide, with potential to inhibit chronic pain. α-Conotoxin GID contains a C-terminal carboxylate, thus substitution with a C-terminal carboxamide results in loss of α4β2 nAChR. α-Conotoxin GID can be isolated from the Conus species .

HY-P5148

α-Conotoxin BuIA	nAChR	Neurological Disease
α-Conotoxin BuIA is a paralytic peptide neurotoxin and a competitive nAChR antagonist, with IC₅₀s of 0.258 nM (α6/α3β2), 1.54 nM (α6/α3β4), 5.72 nM (α3β2), respectively. α-Conotoxin BuIA can be used to distinguish nAChRs containing β2- and β4-subunit, respectively. α-Conotoxin BuIA distinguishes among αxβ2 nAChRs with a rank order potency of α6>α3>α2>α4 .

Cat. No.	Product Name	Target	Research Area

HY-P9911A

Vedolizumab (anti-α4β7-integrin)	Integrin	Inflammation/Immunology
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .

HY-P9911

Vedolizumab 1 Publications Verification Anti-Human lymphocyte α4β7 integrin, Humanized Antibody	Integrin	Inflammation/Immunology Cancer
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.

HY-108831

Natalizumab 1 Publications Verification	Integrin	Inflammation/Immunology
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-P990203

Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32)	Inhibitory Antibodies	Others
Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse LPAM-1/Integrin α4β7.

HY-P99184

Abrilumab	Integrin	Infection Inflammation/Immunology Cancer
Abrilumab is a fully human monoclonal antibody directed against *α4β7*. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .

HY-P9984

Etrolizumab rhuMAb Beta7; RG7413; PRO145223	Integrin	Cancer
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with K_i values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .

HY-108831A

Natalizumab (Solution) 1 Publications Verification	Integrin	Inflammation/Immunology
Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107670

Dihydro-β-erythroidine hydrobromide 1 Publications Verification DHβE hydrobromide	Alkaloids Piperidine Alkaloids Leguminosae Source classification Plants Erythrina	nAChR
Dihydro-β-erythroidine (DHβE) hydrobromide is a potent, orally active, and competitive antagonist of neuronal nAChRs. Dihydro-β-erythroidine hydrobromide shows selectivity for α4β4 and α4β2 nAChRs, with IC₅₀s of 0.19 and 0.37 μM, respectively. Antidepressant-like activities .

HY-N0175

Cytisinicline 1 Publications Verification Cytisine; Sophorine; Baptitoxine	Alkaloids Classification of Application Fields Leguminosae Source classification Pyridine Alkaloids Metabolic Disease Plants Thermopsis lanceolala R.Br. Disease Research Fields	nAChR
Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-N2587

Irigenin	Flavonoids Iridaceae Classification of Application Fields Source classification Phenols Polyphenols Plants Belamcanda chinensis (Linn.) Redouté Disease Research Fields Isoflavones Cancer	Integrin Apoptosis
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking *α9β1* and *α4β1* integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-N10525

3α,4β-Galactotriose	Structural Classification Polysaccharides Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Saccharides	Others
3α,4β-Galactotriose is a galactosyl residue .

HY-N10132

Microgrewiapine A	Malvaceae Structural Classification Alkaloids Microcos paniculata L. Other Alkaloids Source classification Plants	nAChR
Microgrewiapine A is an antagonist of nAChR. Microgrewiapine A inhibits hα4β2 and hα3β4 activity with 60% and 70% inhibition, respectively. Microgrewiapine A has selective cytotoxic against HT-29 human colon cancer cells with an IC₅₀ of 6.8 μM .

HY-A0009

Galanthamine hydrobromide Maximum Cited Publications 12 Publications Verification Galantamine hydrobromide	Structural Classification Alkaloids Other Alkaloids Source classification Plants Amaryllidaceae	Cholinesterase (ChE) nAChR
Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

HY-A0009R

Galanthamine hydrobromide (Standard) Galantamine hydrobromide (Standard)	Structural Classification Alkaloids Source classification Plants Amaryllidaceae	nAChR Cholinesterase (ChE)
Galanthamine (hydrobromide) (Standard) is the analytical standard of Galanthamine (hydrobromide). This product is intended for research and analytical applications. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC₅₀ of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α₃β₄, α₄β₂, α₆β₄ nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) .

Species:	Human (6) Mouse (1) Rat (1) Cynomolgus (1)
Tag:	SUMO (1) His (5) Tag Free (1) Fc (3)
Source:	HEK293 (6) E. coli Cell-free (1) Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P77391

	*IFN-alpha 4* Protein, Cynomolgus (HEK293, Fc)** Interferon alpha-4; IFN-alpha-4; INFA4	Cynomolgus	HEK293
	IFN-alpha 4 (IFNA4), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 4 Protein, Cynomolgus (HEK293, Fc) contains 189 a.a. (M1-N189), produced in HEK293 cells with a C-terminal mFc-tag.

HY-P76403

	*IFN-alpha 4/IFNA4 Protein, Mouse (HEK293, His)* Interferon alpha-4; IFN-alpha-4; INFA4	Mouse	HEK293
	IFN-alpha 4 (IFNA4), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 4/IFNA4 Protein, Mouse (HEK293, His) contains 162 a.a. (C25-E186), produced in HEK293 cells with a C-terminal His-tag.

HY-P702253

	CNGA4 Protein, Human (Cell-Free, His, SUMO) Cyclic nucleotide-gated cation channel alpha-4; Cyclic nucleotide-gated channel alpha-4; CNG channel alpha-4; CNG-4; CNG4	Human	E. coli Cell-free
	The CNGA4 protein is a regulatory subunit of cation-selective cyclic nucleotide-gated (CNG) channels in olfactory sensory neurons that responds to cAMP to induce depolarization. This critical role in odorant signal transduction and adaptation enhances neural responses to olfactory stimulation. CNGA4 Protein, Human (Cell-Free, His, SUMO) is the recombinant human-derived CNGA4 protein, expressed by E. coli Cell-free , with N-6*His, N-SUMO labeled tag. The total length of CNGA4 Protein, Human (Cell-Free, His, SUMO) is 575 a.a., with molecular weight of 82 kDa.

HY-P76983

	*IFN-alpha 4/IFNA4 Protein, Rat (HEK293, Fc)* Interferon alpha-4; Interferon alpha-4B; Interferon alpha-76	Rat	HEK293
	IFN-alpha 4 (IFNA4), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 4/IFNA4 Protein, Rat (HEK293, Fc) contains 166 a.a. (C24-K189), produced in HEK293 cells with a N-terminal hFc-tag.

HY-P75821

	*IFN-alpha 4/IFNA4 Protein, Human (HEK293, Fc)* Interferon alpha-4; Interferon alpha-76; IFNA4	Human	HEK293
	IFN-alpha 4 (IFNA4), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 4/IFNA4 Protein, Human (HEK293, Fc) contains 166 a.a. (C24-D189), produced in HEK293 cells with a N-terminal hFc-tag.

HY-P75822

	*IFN-alpha 4/IFNA4 Protein, Human (sf9, His)* Interferon alpha-4; Interferon alpha-76; IFNA4	Human	Sf9 insect cells
	IFN-alpha 4 (IFNA4), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 4/IFNA4 Protein, Human (sf9, His) contains 189 a.a. (M1-D189), produced in Sf9 insect cells cells with a C-terminal His-tag.

HY-P72615

	*IFN-alpha 4/IFNA4 Protein, Human (HEK293, His)* Interferon alpha-4; Interferon alpha-4B; Interferon alpha-76; Interferon alpha-M1; IFNA4	Human	HEK293
	IFN-alpha 4 (IFNA4), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 4/IFNA4 Protein, Human (HEK293, His) contains 166 a.a. (C24-D189), produced in HEK293 cells cells with a C-terminal His-tag.

HY-P76111

	TPM4 Protein, Human (HEK293, His) Tropomyosin alpha-4 chain; TM30p1; Tropomyosin-4; TPM4	Human	HEK293
	TPM4 protein, binding actin filaments in muscle and non-muscle cells, crucially regulates calcium-dependent muscle contraction, aided by the troponin complex in vertebrates. In smooth muscle cells, TPM4 interacts with caldesmon, contributing to contraction regulation. In non-muscle cells, it stabilizes actin filaments in the cytoskeleton. TPM4's calcium-binding ability, homodimer, and heterodimer formation (with alpha and beta chains) showcase its versatile molecular configurations. TPM4's multifaceted interactions emphasize its essential roles in muscle contraction and cytoskeletal dynamics across diverse cellular contexts. TPM4 Protein, Human (HEK293, His) is the recombinant human-derived TPM4 protein, expressed by HEK293, with N-His, N-6*His labeled tag. The total length of TPM4 Protein, Human (HEK293, His) is 247 a.a., with molecular weight of 35-40 kDa.

HY-P702650

	RPS6KA4 Protein, Human (sf9) RPS6KA4; ribosomal protein S6 kinase, 90kDa, polypeptide 4; ribosomal protein S6 kinase, 90kD, polypeptide 4; ribosomal protein S6 kinase alpha-4; MSK2; RSK B; RSKB; S6K-alpha-4; ribosomal protein kinase B; ribosomal protein S6 kinase alpha 4; 90 kDa ribosomal protein S6 kinase 4; mitogen- and stress-activated protein kinase 2; nuclear mitogen- and stress-activated protein kinase 2; RSK-B	Human	Sf9 insect cells

Cat. No.	Product Name	Chemical Structure

HY-79779S

1-Bromo-4-(bromomethyl)benzene-d6

1-Bromo-4-(bromomethyl)benzene-d₆ is the deuterium labeled 1-Bromo-4-(bromomethyl)benzene[1].

HY-B0942S

Benzethonium-d7 chloride
Benzethonium-d7 chloride is the deuterium labeled Benzethonium chloride. Benzethonium chloride inhibit human recombinant α7 and α4β2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes.

HY-79779S1

1-Bromo-4-(bromomethyl)benzene-d4

1-Bromo-4-(bromomethyl)benzene-d₄ is the deuterium labeled 1-Bromo-4-(bromomethyl)benzene[1].

HY-10019S

Varenicline-d4

Varenicline-d₄ is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC50 value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC50 values of 55 μM and 18 μM, respectively[1]. Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment[2].

HY-A0009S

Galanthamine-d3 hydrobromide

Galanthamine-d₃ (hydrobromide) is deuterium labeled Galanthamine (hydrobromide). Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 µM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3].

HY-10019AS1

Varenicline-d4 hydrochloride

Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

HY-123489S

3α,21-Dihydroxy-5α-pregnan-20-one-d3
3α,21-Dihydroxy-5α-pregnan-20-one-d₃ is the deuterium labeled 3α,21-Dihydroxy-5α-pregnan-20-one. 3α,21-Dihydroxy-5α-pregnan-20-one (THDOC), an endogenous neurosteroid, is a positive modulator of GABAA receptors. 3α,21-Dihydroxy-5α-pregnan-20-one potentiates neuronal response to low concentrations of GABA at α4β1δ GABAA receptors in vitro.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks